Compare DH & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DH | ELDN |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.1M | 229.3M |
| IPO Year | 2021 | 2014 |
| Metric | DH | ELDN |
|---|---|---|
| Price | $1.12 | $2.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $3.43 | ★ $8.50 |
| AVG Volume (30 Days) | 392.1K | ★ 1.2M |
| Earning Date | 05-07-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.28 | 30.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $241,521,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.30 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.97 | $1.35 |
| 52 Week High | $4.70 | $4.60 |
| Indicator | DH | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 35.39 | 57.93 |
| Support Level | $1.07 | $2.48 |
| Resistance Level | $1.29 | $3.15 |
| Average True Range (ATR) | 0.09 | 0.23 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 43.68 | 54.48 |
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.